{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:53:01Z","timestamp":1791154381126,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-15060-6","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:54:56Z","timestamp":1783529696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Addressing real-world data gaps: estimating the uk population cost of crohn\u2019s disease and ulcerative colitis using a flexible cost-of-illness model informed by the optimal patient journey and IBDUK patient survey 2023"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1725-4140","authenticated-orcid":false,"given":"Rachael","family":"MacDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-9429","authenticated-orcid":false,"given":"Nick","family":"Hex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3284-3886","authenticated-orcid":false,"given":"Barbara","family":"Uzdzinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2218-8054","authenticated-orcid":false,"given":"Beth","family":"Umpleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5552-1588","authenticated-orcid":false,"given":"Jessica","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-4550","authenticated-orcid":false,"given":"A. Barney","family":"Hawthorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6452-6763","authenticated-orcid":false,"given":"Richard","family":"Pollok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4278-3720","authenticated-orcid":false,"given":"Jonathan","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-3400","authenticated-orcid":false,"given":"Shahida","family":"Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"15060_CR1","doi-asserted-by":"publisher","unstructured":"Leso V, Gervetti P, Mauro S, Macrini MC, Ercolano ML, Iavicoli I. Shift work and migraine: a systematic review. J Occup Health. 2020;62(1). https:\/\/doi.org\/10.1002\/1348-9585.12116.","DOI":"10.1002\/1348-9585.12116"},{"key":"15060_CR2","unstructured":"Nartey Y, Ratna M, Card TR, Crooks CJ, West J, Tata LJ. Incidence and prevalence of inflammatory bowel disease across the United Kingdom 2021 Available from: https:\/\/crohnsandcolitis.org.uk\/media\/pkamxda4\/uonreport2021_ibd_incidandprev.pdf."},{"issue":"10","key":"15060_CR3","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/apt.15701","volume":"51","author":"D King","year":"2020","unstructured":"King D, Reulen RC, Thomas T, Chandan JS, Thayakaran R, Subramanian A, et al. Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018. Aliment Pharmacol Ther. 2020;51(10):922\u201334. https:\/\/doi.org\/10.1111\/apt.15701.","journal-title":"Aliment Pharmacol Ther"},{"key":"15060_CR4","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","volume":"8","author":"Z Cai","year":"2021","unstructured":"Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med. 2021;8:765474. https:\/\/doi.org\/10.3389\/fmed.2021.765474.","journal-title":"Front Med"},{"issue":"10","key":"15060_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1136\/gut.2004.041616","volume":"53","author":"A Bassi","year":"2004","unstructured":"Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53(10):1471\u201378. https:\/\/doi.org\/10.1136\/gut.2004.041616.","journal-title":"Gut"},{"issue":"3","key":"15060_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/ibd\/izad182","volume":"30","author":"CS Tse","year":"2024","unstructured":"Tse CS, Hunt MG, Brown LA, Lewis JD. Inflammatory bowel diseases-related disability: risk factors, outcomes, and interventions. Inflamm Bowel Dis. 2024;30(3):501\u201307. https:\/\/doi.org\/10.1093\/ibd\/izad182.","journal-title":"Inflamm Bowel Dis"},{"key":"15060_CR7","unstructured":"NHS Arden and Greater East Midlands Commissioning Support Unit. Understanding diagnostic delays in Crohn\u2019s and colitis: an evidence review for Crohn\u2019s and colitis UK, 2022 Available from: https:\/\/crohnsandcolitis.org.uk\/media\/connwcrk\/understanding-diagnostic-delays-in-crohns-and-colitis-executive-summary.pdf."},{"issue":"3","key":"15060_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2105\/AJPH.57.3.424","volume":"57","author":"DP Rice","year":"1967","unstructured":"Rice DP. Estimating the cost of illness. Am J Public Health Nations Health. 1967;57(3):424\u201340. https:\/\/doi.org\/10.2105\/AJPH.57.3.424.","journal-title":"Am J Public Health Nations Health"},{"issue":"3","key":"15060_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/flgastro-2014-100514","volume":"6","author":"N Ghosh","year":"2015","unstructured":"Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. Frontline Gastroenterol. 2015;6(3):169\u201374. https:\/\/doi.org\/10.1136\/flgastro-2014-100514.","journal-title":"Frontline Gastroenterol"},{"issue":"7","key":"15060_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2036.2010.04234.x","volume":"31","author":"RD Cohen","year":"2010","unstructured":"Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31(7):693\u2013707. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04234.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"15060_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1185\/030079908X260790","volume":"24","author":"AP Yu","year":"2008","unstructured":"Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn\u2019s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24(2):319\u201328. https:\/\/doi.org\/10.1185\/030079908X260790.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"15060_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","volume":"5","author":"J Burisch","year":"2020","unstructured":"Burisch J, Vardi H, Schwartz D, Friger M, Kiudelis G, Kup\u010dinskas J, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020;5(5):454\u201364. https:\/\/doi.org\/10.1016\/S2468-1253(20)30012-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"15060_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izz104","volume":"26","author":"K Park","year":"2020","unstructured":"Park K, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, et al. The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & colitis Foundation. Inflamm Bowel Dis. 2020;26(1):1\u201310. https:\/\/doi.org\/10.1093\/ibd\/izz104.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"15060_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-021-06816-3","volume":"21","author":"S Alulis","year":"2021","unstructured":"Alulis S, Vadstrup K, Olsen J, J\u00f8rgensen TR, Qvist N, Munkholm P, et al. The cost burden of Crohn\u2019s disease and ulcerative colitis depending on biologic treatment status \u2013 a Danish register-based study. BMC Health Serv Res. 2021;21(1):1\u20139. https:\/\/doi.org\/10.1186\/s12913-021-06816-3.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"15060_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","volume":"8","author":"J Burisch","year":"2023","unstructured":"Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2023;8(5):458\u201392. https:\/\/doi.org\/10.1016\/S2468-1253(23)00003-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"15060_CR16","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/ibd\/izac144","volume":"29","author":"P Holko","year":"2022","unstructured":"Holko P, Kawalec P, Sajak-Szczerba M, Avedano L, Mossakowska M. Indirect costs of inflammatory bowel diseases: a comparison of patient-reported outcomes across 12 European countries. Inflamm Bowel Dis. 2022;29(5):752\u201362. https:\/\/doi.org\/10.1093\/ibd\/izac144.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"15060_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12876-021-02028-5","volume":"21","author":"L Ruiz-Casas","year":"2021","unstructured":"Ruiz-Casas L, Evans J, Rose A, Pedra GG, Lobo A, Finnegan A, et al. The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe. BMC Gastroenterol. 2021;21(1):456. https:\/\/doi.org\/10.1186\/s12876-021-02028-5.","journal-title":"BMC Gastroenterol"},{"key":"15060_CR18","unstructured":"Craig J, Castro Avila A, Dale V, Bloor K, Hex N. Estimating the economic Value of NIHR Biomedical Research centres and units. 2020."},{"key":"15060_CR19","unstructured":"Mahon J, Littlewood A, Hex N. The added Value of NIHR Biomedical Research centres \u2013 an update to the 2020 economic analysis. 2026."},{"key":"15060_CR20","unstructured":"Office of National Statistics. Population estimates for the UK. 2022 Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesforukenglandandwalesscotlandandnorthernireland, England, Wales, Scotland, and Northern Ireland."},{"key":"15060_CR21","doi-asserted-by":"publisher","unstructured":"Pasvol TJ, Horsfall L, Bloom S, Segal AW, Sabin C, Field N, et al. Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open. 2020;10(7):e036584. https:\/\/doi.org\/10.1136\/bmjopen-2019-036584.","DOI":"10.1136\/bmjopen-2019-036584"},{"key":"15060_CR22","doi-asserted-by":"publisher","unstructured":"Jayasooriya N, Saxena S, Blackwell J, Bottle A, Creese H, Petersen I, et al. Associations between prior healthcare use, time to diagnosis, and clinical outcomes in inflammatory bowel disease: a nationally representative population-based cohort study. BMJ Open Gastroenterol. 2024;11(1):e001371. https:\/\/doi.org\/10.1136\/bmjgast-2024-001371.","DOI":"10.1136\/bmjgast-2024-001371"},{"issue":"10","key":"15060_CR23","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/ibd\/izab287","volume":"28","author":"L Tsai","year":"2022","unstructured":"Tsai L, McCurdy JD, Ma C, Jairath V, Singh S. Epidemiology and natural history of Perianal Crohn\u2019s disease: a systematic review and meta-analysis of population-based cohorts. Inflamm Bowel Dis. 2022;28(10):1477\u201384. https:\/\/doi.org\/10.1093\/ibd\/izab287.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"15060_CR24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.cgh.2024.06.049","volume":"23","author":"J Burisch","year":"2025","unstructured":"Burisch J, Claytor J, Hernandez I, Hou JK, Kaplan GG. The cost of inflammatory bowel disease care: how to make it sustainable. Clin Gastroenterol Hepatol. 2025;23(3):386\u201395. https:\/\/doi.org\/10.1016\/j.cgh.2024.06.049.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"15060_CR25","doi-asserted-by":"publisher","unstructured":"Noor NM, Davies N, Tahir W, Bond S, Dowling F, Patel KV, et al. Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional \u201cstep-up\u201d care for patients with active Crohn\u2019s disease: a cost-effectiveness analysis from the PROFILE trial. J Crohns Colitis. 2025;19(9):jjaf150. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf150.","DOI":"10.1093\/ecco-jcc\/jjaf150"},{"key":"15060_CR26","unstructured":"Centre NCG. Crohn\u2019s disease. 2012."},{"key":"15060_CR27","unstructured":"NICE. Evidence reviews for induction of remission in mild-to-moderate ulcerative colitis [NG130]. 2019 Available from: https:\/\/www.nice.org.uk\/guidance\/ng130\/evidence\/induction-of-remission-in-mildtomoderate-ulcerative-colitis-pdf-6777260893B."},{"issue":"10","key":"15060_CR28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/apt.14334","volume":"46","author":"CP Selinger","year":"2017","unstructured":"Selinger CP, Parkes GC, Bassi A, Fogden E, Hayee B, Limdi JK, et al. A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(10):964\u201373. https:\/\/doi.org\/10.1111\/apt.14334.","journal-title":"Aliment Pharmacol Ther"},{"key":"15060_CR29","unstructured":"UK Inflammatory Bowel Disease (IBD) audit: Round. Healthcare Qual Improv Partnersh; 2012 - 2014;4. Available from: https:\/\/www.data.gov.uk\/dataset\/65eef566-030d-45b2-a0e9-884bea6807b5\/uk-inflammatory-bowel-disease-ibd-audit-round-4-2012-2014."},{"issue":"1","key":"15060_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/flgastro-2013-100348","volume":"5","author":"LYW Lee","year":"2014","unstructured":"Lee LYW, Gardezi AS, Santharam V, Boyd J, Lanzon-Miller S. Effect of azathioprine intolerance on outcomes of inflammatory bowel disease: a cross-sectional study. Frontline Gastroenterol. 2014;5(1):40\u201343. https:\/\/doi.org\/10.1136\/flgastro-2013-100348.","journal-title":"Frontline Gastroenterol"},{"key":"15060_CR31","volume-title":"StatPearls","author":"A Hodgens","year":"2025","unstructured":"Hodgens A, Corticosteroids ST. StatPearls. Treasure Island (FL); 2025."},{"key":"15060_CR32","unstructured":"BNF. Balsalazide sodium Available from: https:\/\/bnf.nice.org.uk\/drugs\/balsalazide-sodium\/."},{"key":"15060_CR33","unstructured":"BNF. Mesalazine. Available from: https:\/\/bnf.nice.org.uk\/drugs\/mesalazine\/."},{"key":"15060_CR34","unstructured":"BNF. Olsalazine sodium Available from: https:\/\/bnf.nice.org.uk\/drugs\/olsalazine-sodium\/."},{"key":"15060_CR35","unstructured":"NICE. Rheumatoid arthritis: how common is it? 2024 Available from: https:\/\/cks.nice.org.uk\/topics\/rheumatoid-arthritis\/background-information\/prevalence-incidence\/."},{"issue":"12","key":"15060_CR36","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/rheumatology\/kead586","volume":"63","author":"KL Druce","year":"2024","unstructured":"Druce KL, Yimer BB, Humphreys J, Njuki LN, Bourke D, Li M, et al. The epidemiology of psoriatic arthritis in the UK: a health intelligence analysis of UK primary care electronic Health Records 1991\u20132020. Rheumatol (Oxford). 2024;63(12):3346\u201352. https:\/\/doi.org\/10.1093\/rheumatology\/kead586.","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"15060_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41927-023-00370-7","volume":"8","author":"de Souza S","year":"2024","unstructured":"de Souza S, Williams R, Nikiphorou E, de Souza S. Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study. BMC Rheumatol. 2024;8(1):1. https:\/\/doi.org\/10.1186\/s41927-023-00370-7.","journal-title":"BMC Rheumatol"},{"key":"15060_CR38","unstructured":"3) NRCS-v. Available from: https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/."},{"key":"15060_CR39","unstructured":"ONS. Estimates of the population for England and Wales. [mid-2022 local authority edition of this dataset.]. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/estimatesofthepopulationforenglandandwales."},{"issue":"9","key":"15060_CR40","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s10620-016-4195-1","volume":"61","author":"TR Card","year":"2016","unstructured":"Card TR, Langan SM, Chu TPC. Extra-gastrointestinal manifestations of inflammatory bowel disease may Be less common than Previously reported. Dig Dis Sci. 2016;61(9):2619\u201326. https:\/\/doi.org\/10.1007\/s10620-016-4195-1.","journal-title":"Dig Dis Sci"},{"issue":"15","key":"15060_CR41","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.12998\/wjcc.v7.i15.1908","volume":"7","author":"D Sgambato","year":"2019","unstructured":"Sgambato D, Gimigliano F, De Musis C, Moretti A, Toro G, Ferrante E, et al. Bone alterations in inflammatory bowel diseases. WJCC. 2019;7(15):1908\u201325. https:\/\/doi.org\/10.12998\/wjcc.v7.i15.1908.","journal-title":"WJCC"},{"issue":"5","key":"15060_CR42","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/hep.21537","volume":"45","author":"F Parente","year":"2007","unstructured":"Parente F, Pastore L, Bargiggia S, Cucino C, Greco S, Molteni M, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology. 2007;45(5):1267\u201374. https:\/\/doi.org\/10.1002\/hep.21537.","journal-title":"Hepatology"},{"issue":"8","key":"15060_CR43","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1097\/MIB.0000000000000832","volume":"22","author":"T Bessissow","year":"2016","unstructured":"Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(8):1937\u201344. https:\/\/doi.org\/10.1097\/MIB.0000000000000832.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"15060_CR44","doi-asserted-by":"publisher","first-page":"19954","DOI":"10.1038\/s41598-021-98843-7","volume":"11","author":"J Voss","year":"2021","unstructured":"Voss J, Schneider CV, Kleinjans M, Bruns T, Trautwein C, Strnad P. Hepatobiliary phenotype of individuals with chronic intestinal disorders. Sci Rep. 2021;11(1):19954. https:\/\/doi.org\/10.1038\/s41598-021-98843-7.","journal-title":"Sci Rep"},{"key":"15060_CR45","unstructured":"NHS. NHS RightCare scenario: the variation between sub-optimal and optimal pathways 2017 Available from: https:\/\/www.england.nhs.uk\/rightcare\/wp-content\/uploads\/sites\/40\/2017\/02\/rightcare-susans-story-full-narrative.pdf."},{"issue":"1","key":"15060_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"15060_CR47","unstructured":"Office for National Statistics. Census and Labour Market Statistics. 2023 Available from: https:\/\/www.nomisweb.co.uk\/query\/select\/getdatasetbytheme.asp?theme=73."},{"issue":"6","key":"15060_CR48","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, Gower\u2013Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785\u201394.e4. https:\/\/doi.org\/10.1053\/j.gastro.2011.01.055.","journal-title":"Gastroenterology"},{"issue":"5","key":"15060_CR49","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1097\/MIB.0000000000000742","volume":"22","author":"ML Ganz","year":"2016","unstructured":"Ganz ML, Sugarman R, Wang R, Hansen BB, H\u00e5kan-Bloch J. The economic and Health-related impact of Crohn\u02bcs disease in the United States. Inflamm Bowel Dis. 2016;22(5):1032\u201341. https:\/\/doi.org\/10.1097\/MIB.0000000000000742.","journal-title":"Inflamm Bowel Dis"},{"key":"15060_CR50","doi-asserted-by":"publisher","unstructured":"Mandel MD, B\u00e1lint A, Lov\u00e1sz BD, Gul\u00e1csi L, Strb\u00e1k B, Golovics PA, et al. Erratum to: work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ. 2014;15(S1):S129\u2013129. https:\/\/doi.org\/10.1007\/s10198-014-0613-5.","DOI":"10.1007\/s10198-014-0613-5"},{"issue":"2","key":"15060_CR51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5114\/aoms.2016.59254","volume":"2","author":"P Kawalec","year":"2016","unstructured":"Kawalec P. Indirect costs of inflammatory bowel diseases: Crohn\u2019s disease and ulcerative colitis. A systematic review. Aoms. 2016;2(2):295\u2013302. https:\/\/doi.org\/10.5114\/aoms.2016.59254.","journal-title":"Aoms"},{"issue":"7","key":"15060_CR52","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/MIB.0000000000000399","volume":"21","author":"A Zand","year":"2015","unstructured":"Zand A, van Deen WK, Inserra EK, Hall L, Kane E, Centeno A, et al. Presenteeism in inflammatory bowel diseases: a hidden problem with significant economic impact. Inflamm Bowel Dis. 2015;21(7):1623\u201330. https:\/\/doi.org\/10.1097\/MIB.0000000000000399.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"15060_CR53","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.cgh.2019.07.022","volume":"18","author":"GR Lichtenstein","year":"2020","unstructured":"Lichtenstein GR, Shahabi A, Seabury SA, Lakdawalla DN, Espinosa OD, Green S, et al. Lifetime economic burden of Crohn\u2019s disease and ulcerative colitis by age at diagnosis. Clin Gastroenterol Hepatol. 2020;18(4):889\u201397.e10. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.022.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"40","key":"15060_CR54","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.3748\/wjg.v16.i40.5024","volume":"16","author":"K Umanskiy","year":"2010","unstructured":"Umanskiy K. Health related quality of life in inflammatory bowel disease: the impact of surgical therapy. WJG. 2010;16(40):5024\u201334. https:\/\/doi.org\/10.3748\/wjg.v16.i40.5024.","journal-title":"WJG"},{"issue":"10","key":"15060_CR55","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/01.mib.0000179467.01748.99","volume":"11","author":"T Bernklev","year":"2005","unstructured":"Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005;11(10):909\u201318. https:\/\/doi.org\/10.1097\/01.mib.0000179467.01748.99.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"15060_CR56","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/01.MIB.0000159661.55028.56","volume":"11","author":"F Casellas","year":"2005","unstructured":"Casellas F, Arenas JI, Baudet JS, F\u00e1bregas S, Garc\u00eda N, Gelabert J, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11(5):488\u201396. https:\/\/doi.org\/10.1097\/01.MIB.0000159661.55028.56.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"15060_CR57","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses\u2014part I. Inflamm Bowel Dis. 2018;24(4):742\u201351. https:\/\/doi.org\/10.1093\/ibd\/izx100.","journal-title":"Inflamm Bowel Dis"},{"key":"15060_CR58","unstructured":"NHS RightCare. Hannah\u2019s story: inflammatory bowel disease. An implementation support tool that highlights the variation between optimal and suboptimal care. 2024 Available from: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2024\/06\/RightCare-IBD-scenario-June-2024.pdf."},{"issue":"1","key":"15060_CR59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/apt.16867","volume":"56","author":"M Lyons","year":"2022","unstructured":"Lyons M, Derikx LAAP, Fulforth J, McCall S, Plevris N, Jenkinson PW, et al. Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis. Aliment Pharmacol Ther. 2022;56(1):67\u201376. https:\/\/doi.org\/10.1111\/apt.16867.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"15060_CR60","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S2468-1253(24)00264-4","volume":"9","author":"S Din","year":"2024","unstructured":"Din S, Segal J, Blackwell J, Gros B, Black CJ, Ford AC. Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024;9(11):1020\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(24)00264-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"15060_CR61","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S2468-1253(24)00233-4","volume":"9","author":"B Gros","year":"2024","unstructured":"Gros B, Blackwell J, Segal J, Black CJ, Ford AC, Din S. Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024;9(11):1030\u201340. https:\/\/doi.org\/10.1016\/S2468-1253(24)00233-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"15060_CR62","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/codi.15491","volume":"23","author":"PW Jenkinson","year":"2021","unstructured":"Jenkinson PW, Plevris N, Lyons M, Grant R, Fulforth J, Kirkwood K, et al. Analysis of colectomy rates for ulcerative colitis in pre- and postbiological eras in Lothian, Scotland. Colorectal Dis. 2021;23(5):1175\u201383. https:\/\/doi.org\/10.1111\/codi.15491.","journal-title":"Colorectal Dis"},{"issue":"5","key":"15060_CR63","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","volume":"9","author":"NM Noor","year":"2024","unstructured":"Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(5):415\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(24)00034-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"15060_CR64","first-page":"14","volume":"31","author":"MPC Santos","year":"2018","unstructured":"Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol. 2018;31(1):14\u201323.","journal-title":"Ann Gastroenterol"},{"issue":"6","key":"15060_CR65","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/gutjnl-2022-328174","volume":"72","author":"EW Lopes","year":"2023","unstructured":"Lopes EW, Chan SSM, Song M, Ludvigsson JF, H\u00e5kansson N, Lochhead P, et al. Lifestyle factors for the prevention of inflammatory bowel disease. Gut. 2023;72(6):1093\u2013100. https:\/\/doi.org\/10.1136\/gutjnl-2022-328174.","journal-title":"Gut"},{"issue":"11","key":"15060_CR66","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S2468-1253(17)30248-0","volume":"2","author":"CY Ponsioen","year":"2017","unstructured":"Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2(11):785\u201392. https:\/\/doi.org\/10.1016\/S2468-1253(17)30248-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"15060_CR67","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/S2468-1253(20)30117-5","volume":"5","author":"TW Stevens","year":"2020","unstructured":"Stevens TW, Haasnoot ML, D\u2019Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol. 2020;5(10):900\u201307. https:\/\/doi.org\/10.1016\/S2468-1253(20)30117-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"15060_CR68","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1053\/j.gastro.2023.05.051","volume":"165","author":"M Agrawal","year":"2023","unstructured":"Agrawal M, Ebert AC, Poulsen G, Ungaro RC, Faye AS, Jess T, et al. Early ileocecal resection for Crohn\u2019s disease is associated with improved long-term outcomes compared with anti-tumor necrosis factor therapy: a population-based cohort study. Gastroenterology. 2023;165(4):976\u201385.e3. https:\/\/doi.org\/10.1053\/j.gastro.2023.05.051.","journal-title":"Gastroenterology"},{"key":"15060_CR69","unstructured":"House of Lords Public Services Committee. House of lords public services committee report: homecare medicines services. 2024 Available from: https:\/\/lordslibrary.parliament.uk\/house-of-lords-public-services-committee-report-homecare-medicines-services\/#heading-1."},{"key":"15060_CR70","unstructured":"NHS England. NHS set to save record \u00a3300 million on the NHS\u2019s highest drug spend. 2018 Available from: https:\/\/www.england.nhs.uk\/2018\/11\/nhs-set-to-save-record-300-million-on-the-nhss-highest-drug-spend\/."},{"issue":"1","key":"15060_CR71","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"GG Kaplan","year":"2020","unstructured":"Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;18(1):56\u201366. https:\/\/doi.org\/10.1038\/s41575-020-00360-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"15060_CR72","unstructured":"IBD UK. The state of IBD care in the UK,. 2024 Available from: https:\/\/s3.eu-west-2.amazonaws.com\/sr-crohns-craft\/documents\/IBD-UK-National-Report_7OCT_v9_WITH-HYPERLINKS_compressed.pdf."},{"issue":"1","key":"15060_CR73","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S2468-1253(24)00350-9","volume":"10","author":"S Din","year":"2025","unstructured":"Din S, Rodrigues A, Avery P, Tucker N, Attwood D, Ainley R, et al. Symptoms collaborative group. Primary care diagnostic pathways for lower gastrointestinal symptoms. Lancet Gastroenterol Hepatol. 2025;10(1):9\u201311. https:\/\/doi.org\/10.1016\/S2468-1253(24)00350-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"15060_CR74","unstructured":"What\u2019s up with my Gut? The path to a correct diagnosis Available from: https:\/\/www.whatsupwithmygut.org.uk\/."},{"key":"15060_CR75","doi-asserted-by":"publisher","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749.1\u201353. https:\/\/doi.org\/10.1136\/gut.2005.082909.","DOI":"10.1136\/gut.2005.082909"},{"issue":"5","key":"15060_CR76","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/flgastro-2023-102409","volume":"14","author":"MN Quraishi","year":"2023","unstructured":"Quraishi MN, Dobson E, Ainley R, Din S, Wakeman R, Cummings F, et al. Establishing key performance indicators for inflammatory bowel disease in the UK. Frontline Gastroenterol. 2023;14(5):407\u201314. https:\/\/doi.org\/10.1136\/flgastro-2023-102409.","journal-title":"Frontline Gastroenterol"},{"key":"15060_CR77","doi-asserted-by":"publisher","unstructured":"Stark R, HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 2006;24(8):797\u2013814. https:\/\/doi.org\/10.2165\/00019053-200624080-00006.","DOI":"10.2165\/00019053-200624080-00006"},{"issue":"3","key":"15060_CR78","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/j.gastro.2006.05.052","volume":"131","author":"S Odes","year":"2006","unstructured":"Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131(3):719\u201328. https:\/\/doi.org\/10.1053\/j.gastro.2006.05.052.","journal-title":"Gastroenterology"},{"issue":"1","key":"15060_CR79","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2036.2008.03709.x","volume":"28","author":"J Lindsay","year":"2008","unstructured":"Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn\u2019s disease \u2013 modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28(1):76\u201387. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03709.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"15060_CR80","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/j.1365-2036.2008.03839.x","volume":"28","author":"HH Tsai","year":"2008","unstructured":"Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008;28(10):1230\u201339. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03839.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"15060_CR81","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/00365521.2021.1908416","volume":"56","author":"R Rankala","year":"2021","unstructured":"Rankala R, Mattila K, Voutilainen M, Mustonen A. Inflammatory bowel disease-related economic costs due to presenteeism and absenteeism. Scand J Gastroenterol. 2021;56(6):687\u201392. https:\/\/doi.org\/10.1080\/00365521.2021.1908416.","journal-title":"Scand J Gastroenterol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-15060-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15060-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15060-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:30:31Z","timestamp":1791153031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-15060-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15060"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-15060-6","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Participation in the 2023 UK IBD Patient Survey was voluntary. Completion of the survey was taken as informed consent to participate, and no identifiable patient data was stored, so all responses were anonymous for analysis and publication. Ethics approval was not required for NHS service improvement surveys that are anonymous.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participation in the 2023 UK IBD Patient Survey was voluntary and respondents were informed that anonymised, aggregate results would be published. Completion of the survey was taken as informed consent to participate, and all responses were anonymised prior to analysis and publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SD is Chair of British Society of Gastroenterology Inflammatory Bowel Disease Committee and MHRA Gastroenterology, Rheumatology, Immunology & Dermatology Expert Advisory Group. Reports grants from Crohn\u2019s & Colitis UK, The Helmsley Charitable Trust, Edinburgh and Lothians Health Foundation, Pathological Society of Great Britain and Northern Ireland, and Lord Leonard and Lady Estelle Wolfson Foundation; consultant to AbbVie, Eli Lilly, honoraria or speaker fees from Janssen, Takeda, Ferring, Dr Falk, and AbbVie and meeting and travel grants from AbbVie, Janssen, Takeda, Lilly, and Dr Falk.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1354"}}